IN8bio Presents Phase 1 INB-100 Trial Data At EHA 2024; 100% Of Evaluable Leukemia Patients Remain Alive, Progression-Free, And In Durable CR Through One Year; Demonstrates In Vivo Expansion And Persistence Of Haplo-Matched Allogeneic Gamma-Delta T Cell Therapy
$INAB
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
- 100% of treated leukemia patients (n=10/10) achieved durable complete remission (CR) at 1-year, including high-risk and relapsed acute myeloid leukemia (AML) patients who had previously failed multiple lines of therapy, including CAR-T.
- Data continue to show long-term in vivo expansion and persistence of allogeneic gamma-delta T cells 365 days following a single administration, demonstrating first-ever durable persistence and expansion of an allogeneic cellular therapy.
- The Company will host a conference call at 4:15 pm ET. Use this link to participate. A listen-only version of the webcast is available here.